The Incruse Ellipta inhaler is a once-daily dry powder inhaler used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It contains umeclidinium, a long-acting muscarinic antagonist (LAMA) [1][2].
How does Incruse Ellipta work for COPD?
Incruse Ellipta works by relaxing the muscles around the airways in the lungs, which helps to open up the airways and make breathing easier [1][3]. This action is achieved through umeclidinium, which blocks the effect of acetylcholine, a substance that causes airway muscles to constrict [3]. By preventing this constriction, the inhaler provides sustained bronchodilation, a key goal in managing COPD symptoms [3].
What is the active ingredient in Incruse Ellipta?
The active ingredient in Incruse Ellipta is umeclidinium [1][2]. Umeclidinium is a specific type of medication known as a long-acting muscarinic antagonist (LAMA) [2][4].
How often should Incruse Ellipta be used?
Incruse Ellipta is administered once daily [1].
What are the common side effects of Incruse Ellipta?
Common side effects associated with Incruse Ellipta include nasopharyngitis (common cold symptoms), upper respiratory tract infection, and headache [1].
Can Incruse Ellipta be used with other COPD medications?
Yes, Incruse Ellipta can be used in conjunction with other COPD medications, such as a long-acting beta2-agonist (LABA) and/or an inhaled corticosteroid (ICS), although it is not indicated for the relief of acute bronchospasm [1][5]. It is often prescribed as a monotherapy or as part of a triple therapy regimen [1][5].
What is the patent status for Incruse Ellipta?
Information on the patent status of Incruse Ellipta and its active ingredient, umeclidinium, can be found through specialized drug patent tracking services [6]. These resources can provide details on patent expiration dates and potential challenges to intellectual property [6].
Who manufactures Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [1][7]. GSK is a global pharmaceutical company that develops and markets a range of respiratory medications [7].